Cargando…
Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects joints with swelling and progressive joint destruction. The pathology leads to a progressive disability with an impact on the quality of life of the patients. Strategies to reduce in-patient care costs could have a considerabl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560192/ https://www.ncbi.nlm.nih.gov/pubmed/31239737 http://dx.doi.org/10.2147/CEOR.S192910 |
_version_ | 1783425921131216896 |
---|---|
author | Benucci, Maurizio Damiani, Arianna Manfredi, Mariangela Infantino, Maria Grossi, Valentina Li Gobbi, Francesca |
author_facet | Benucci, Maurizio Damiani, Arianna Manfredi, Mariangela Infantino, Maria Grossi, Valentina Li Gobbi, Francesca |
author_sort | Benucci, Maurizio |
collection | PubMed |
description | Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects joints with swelling and progressive joint destruction. The pathology leads to a progressive disability with an impact on the quality of life of the patients. Strategies to reduce in-patient care costs could have a considerable impact on lowering the direct medical costs of RA in Italy. Abatacept, a selective T-cell costimulation modulator, is a valuable treatment option for patients with moderate-to-severe RA. A search using the keywords “cost-effectiveness analysis", "budget impact model", "abatacept", and "rheumatoid arthritis” was carried out on PubMed. Abatacept in the first- and second-treatment lines has been evaluated in our research. We evaluated patients with inadequate MTX response, inadequate anti-TNF agents response, switch studies and real-world data. Furthermore, in our research, we evaluated the main head-to-head studies published. |
format | Online Article Text |
id | pubmed-6560192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65601922019-06-25 Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life Benucci, Maurizio Damiani, Arianna Manfredi, Mariangela Infantino, Maria Grossi, Valentina Li Gobbi, Francesca Clinicoecon Outcomes Res Review Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects joints with swelling and progressive joint destruction. The pathology leads to a progressive disability with an impact on the quality of life of the patients. Strategies to reduce in-patient care costs could have a considerable impact on lowering the direct medical costs of RA in Italy. Abatacept, a selective T-cell costimulation modulator, is a valuable treatment option for patients with moderate-to-severe RA. A search using the keywords “cost-effectiveness analysis", "budget impact model", "abatacept", and "rheumatoid arthritis” was carried out on PubMed. Abatacept in the first- and second-treatment lines has been evaluated in our research. We evaluated patients with inadequate MTX response, inadequate anti-TNF agents response, switch studies and real-world data. Furthermore, in our research, we evaluated the main head-to-head studies published. Dove 2019-06-07 /pmc/articles/PMC6560192/ /pubmed/31239737 http://dx.doi.org/10.2147/CEOR.S192910 Text en © 2019 Benucci et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Benucci, Maurizio Damiani, Arianna Manfredi, Mariangela Infantino, Maria Grossi, Valentina Li Gobbi, Francesca Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life |
title | Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life |
title_full | Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life |
title_fullStr | Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life |
title_full_unstemmed | Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life |
title_short | Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life |
title_sort | abatacept: from a budget impact model to cost-effectiveness analysis – data from rct and real life |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560192/ https://www.ncbi.nlm.nih.gov/pubmed/31239737 http://dx.doi.org/10.2147/CEOR.S192910 |
work_keys_str_mv | AT benuccimaurizio abataceptfromabudgetimpactmodeltocosteffectivenessanalysisdatafromrctandreallife AT damianiarianna abataceptfromabudgetimpactmodeltocosteffectivenessanalysisdatafromrctandreallife AT manfredimariangela abataceptfromabudgetimpactmodeltocosteffectivenessanalysisdatafromrctandreallife AT infantinomaria abataceptfromabudgetimpactmodeltocosteffectivenessanalysisdatafromrctandreallife AT grossivalentina abataceptfromabudgetimpactmodeltocosteffectivenessanalysisdatafromrctandreallife AT ligobbifrancesca abataceptfromabudgetimpactmodeltocosteffectivenessanalysisdatafromrctandreallife |